Anticoagulation Therapy In Risky Geriatric Cardiac Patients In the realm of cardiovascular health, the coexistence of atrial fibrillation (AF) with heart failure (HF) presents a significant challenge for anticoagulation, particularly in the aging population. Uncertainties abound regarding treatment efficacy and patient outcomes. The All Nippon AF In the Elderly (ANAFIE) Registry,
Tag: cardiovascular diseases
Constipation Effect On Readmission In Heart Failure Patients
Constipation Effect On Readmission In Heart Failure Patients Constipation, a prevalent gastrointestinal disorder in Japan, affects 34.8 per 1000 individuals, rising with age and linked to factors like reduced dietary fiber and physical activity. Chronic constipation, unlike other functional gastrointestinal diseases, exhibits a significantly higher mortality risk, particularly notable in cardiovascular
Bariatric Surgery In Hypertrophic Cardiomyopathy Patients
Bariatric Surgery In Hypertrophic Cardiomyopathy Patients Overview Existing research has hinted at a link between obesity and increased risk of acute cardiovascular events. Bariatric surgery has been shown to mitigate this risk; however, its impact on patients with both obesity and hypertrophic cardiomyopathy (HCM) remains unclear. This study aimed to assess whether
Retinal Nerve Fiber Wedge Defects In Glaucoma And Heart Disease
Retinal Nerve Fiber Wedge Defects In Glaucoma And Heart Disease The Study The study aimed to investigate the connection between localized vascular and retinal nerve fiber layer (RNFL) loss and an individual's genetic predisposition to both glaucoma and cardiovascular disease. Researchers used a statistical tool called polygenic risk scores (PRS) to assess
Chronic Hyponatremia in Acute Heart Failure
Chronic Hyponatremia in Acute Heart Failure Overview This study aimed to comprehensively assess hyponatremia in patients with acute heart failure (AHF), focusing on its prevalence, associations, hospital course, and post-discharge outcomes. The research analyzed a cohort of 8,298 AHF patients from the European Society of Cardiology Heart Failure Long-Term Registry, regardless of
Finerenone Therapy In CKD and Type 2 Diabetes
Finerenone Therapy In CKD and Type 2 Diabetes Overview The aim of this study is to assess the effect of finerenone on the duration, progression and complications of type 2 diabetes mellitus. This was achieved by estimating the values of baseline glycated hemoglobin (HbA1c) levels, glycated hemoglobin level variabilities, and the development
Cholesterol Screening To Aid In Glaucoma Detection
Cholesterol Screening To Aid In Glaucoma Detection Overview Although intraocular pressure is the primary risk factor for glaucoma, additional risk factors should also be considered. This systematic review and meta-analysis summarize the evidence of the association between cholesterol parameters (total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels) and glaucoma and
Aprocitentan in resistant hypertension
Aprocitentan in resistant hypertension Since the 1960s, modern studies of hypertension and the availability of antihypertensive drugs have significantly improved blood pressure control. However, it has reached a plateau in high-income countries in the past decade. Many patients who have uncontrolled BP despite three antihypertensive treatments at optimal dose and from
Predicting cardiovascular disease with body mass index
Predicting cardiovascular disease with Body Mass Index BMI and CVD: An Introduction Obesity, as indexed by the high body mass index (BMI), is a major risk factor for cardiovascular disease (CVD). About 60 - 80% of patients with CVD are overweight. However, there are mixed findings on the effect of decreasing BMI
Hypertension Screening for Cardiovascular Health
Hypertension Screening for Cardiovascular Health Introduction Hypertension is a contributing risk factor for cardiovascular health. In the recent European Society of Cardiology (ESC) guidelines, the main recommendation for antihypertensive treatment of patients was regarded by the future risk of cardiovascular (CV) mortality, CV disease, or total mortality. The guideline state that the
